Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Aaron M. Goodman, Shumei Kato, Lyudmila Bazhenova, +6

Molecular Cancer Therapeutics

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

F. Michael Yakes, Jason Chen, Jenny Tan, +14

Molecular Cancer Therapeutics

AngiogenesisNovel MetMedicineTumor GrowthVegfr Signaling +11

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

David W. Fry, Patricia J. Harvey, Paul R. Keller, +8

Molecular Cancer Therapeutics

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, +14

Molecular Cancer Therapeutics

Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer

Matt I. Gross, Susan D. Demo, Jennifer B. Dennison, +16

Molecular Cancer Therapeutics

Glutamine ConsumptionBreast OncologyAntitumor ActivityPathologyTumor Biology +16

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs <i>In vitro</i> and <i>In vivo</i>

Hiroshi Hirai, Hiroshi Sootome, Yoko Nakatsuru, +8

Molecular Cancer Therapeutics

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

Junko Murai, Shar-yin N. Huang, Amèlie Renaud, +7

Molecular Cancer Therapeutics

Molecular PharmacologyMedicinal ChemistryBioorganic ChemistryCatalytic Parp InhibitionBiochemistry +13

Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells

Raoul Tibes, Yihua Qiu, Yiling Lu, +4

Molecular Cancer Therapeutics

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

James G. Christensen, Helen Y. Zou, Maria E. Arango, +7

Molecular Cancer Therapeutics

Signal TransducersImmunologyCell DeathExperimental ModelsCancer Biology +21

Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin

Olga Kovalchuk, Jody Filkowski, James Meservy, +3

Molecular Cancer Therapeutics